Bli medlem
Bli medlem

Du är här


Zealand Pharma: Zealand reports Q4 2016 Lyxumia® royalty revenue

Company announcement - No. 3 / 2017

Zealand reports Q4 2016 Lyxumia® royalty revenue

Zealand receives royalty revenue of DKK 5.3 million / €0.7 million in Q4 2016
(and DKK 24.4 million / €3.3 million
in full year 2016) from sales of Lyxumia® by Sanofi outside the United States.

Copenhagen, 8 February 2017

- Zealand Pharma (Zealand) reports royalty revenue from Sanofi's sales of
Lyxumia® (lixisenatide) outside the United States of DKK 5.3 million / €0.7
million for Q4 2016. Zealand's annual royalty revenue in respect of Lyxumia®
amounted to DKK 24.3 million / €3.3 million in 2016.

Lixisenatide is a once-daily prandial GLP-1 receptor agonist for the treatment
of patients with type 2 diabetes and was invented by Zealand. Zealand
licensed the global development and commercialization rights to lixisenatide
to Sanofi. Lixisenatide is marketed under the brand name Lyxumia® in over 45
countries and was launched in the United States under the brand name
Adlyxin(TM) in January 2017.

Sanofi has also developed a combination of lixisenatide and insulin glargine
100 units/mL (Lantus®), which was approved by: (i) the US Food and Drug
Administration in November 2017 and is being marketed under the brand name
Soliqua(TM)100/33 in the United States and (ii) the European Medicines Agency
in January 2017 and is expected to be marketed in Europe under the brand name

Since January 2017, Soliqua(TM) 100/33 (insulin glargine 100
Units/mL&lixisenatide 33 mcg/mL injection) has been available by prescription
in US pharmacies. Soliqua(TM) 100/33 is approved in the United States as an
adjunct to diet and exercise to improve glycemic control in adults with type
2 diabetes mellitus inadequately controlled on basal insulin (less than 60
Units daily) or lixisenatide alone. Sanofi has announced that it expects to
launch marketing of Suliqua(TM)
in certain EU countries in the second quarter of 2017.

For further information, please contact:

Britt Meelby Jensen,
President and Chief Executive Officer
Tel: +45
51 67 61 28,

Mats Blom, Senior
Vice President, Chief Financial Officer
Tel: +4531 53 79 73

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology
company focused on the discovery, design and development of innovative
peptide-based medicines. Zealand has a portfolio of medicines and product
candidates under license collaborations with Sanofi, Boehringer Ingelheim and
Helsinn, and a pipeline of proprietary product candidates that primarily
target specialty diseases with significant unmet needs.

Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1
analogue for the treatment of type 2 diabetes, is licensed to Sanofi.
Lixisenatide is marketed as Adlyxin(TM) in the US and Lyxumia®in the rest of
the world. Lixisenatide has been developed in a combination with basal
insulin glargine (Lantus®) and is marketed as Soliqua(TM) 100/33 in the US
and has been approved as Suliqua(TM) in Europe.

Zealand's pipeline includes: dasiglucagon* (ZP4207, single-dose rescue
treatment) for acute, severe hypoglycemia (phase II); glepaglutide* (ZP1848)
for short bowel syndrome (phase II); dasiglucagon* (ZP4207, multiple-dose
version) intended for use in a dual-hormone artificial pancreas system for
better hypoglycemia control and diabetes management (phase II) and other
earlier-stage clinical and preclinical peptide therapeutics.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information
about the company's business and activities, please visit or follow Zealand on Twitter @ZealandPharma.

* Dasiglucagon and glepaglutide are proposed International Nonproprietary
Names (pINN).
[1]Approved in Europe in 2 doses (insulin 100 units/ml with lixisenatide 33 or
50 micrograms/ml)

03-17_0208 Company announcement Lyxumia Royalty

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Zealand Pharma via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.